{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:41:47Z","timestamp":1779205307106,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA254961"],"award-info":[{"award-number":["R01CA254961"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA186781"],"award-info":[{"award-number":["CA186781"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA254961"],"award-info":[{"award-number":["CA254961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01417-3","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:44:27Z","timestamp":1763761467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance"],"prefix":"10.1038","volume":"15","author":[{"given":"Joel-Sean","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishore","family":"Garapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5791-727X","authenticated-orcid":false,"given":"Kiran K.","family":"Mangalaparthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6679-518X","authenticated-orcid":false,"given":"Yogesh","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-6127","authenticated-orcid":false,"given":"Akhilesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-1222","authenticated-orcid":false,"given":"Richard K.","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1417_CR1","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024;5:1267\u201384.","journal-title":"Nat Cancer"},{"key":"1417_CR2","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1021\/acs.jproteome.9b00503","volume":"18","author":"V Ignjatovic","year":"2019","unstructured":"Ignjatovic V, Geyer PE, Palaniappan KK, Chaaban JE, Omenn GS, Baker MS, et al. Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data. J Proteome Res. 2019;18:4085\u201397.","journal-title":"J Proteome Res"},{"key":"1417_CR3","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","volume":"8","author":"MSY Tan","year":"2024","unstructured":"Tan MSY, Chen Y, Smith EL. Beyond BCMA: newer immune targets in myeloma. Blood Adv. 2024;8:4433\u201346.","journal-title":"Blood Adv"},{"key":"1417_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"},{"key":"1417_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35378-z","volume":"13","author":"C Xu","year":"2023","unstructured":"Xu C, Gao M, Zhang J, Fu Y. IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma. Sci Rep. 2023;13:8528.","journal-title":"Sci Rep."},{"key":"1417_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1365-2141.2011.08941.x","volume":"156","author":"N Hosen","year":"2012","unstructured":"Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol. 2012;156:213\u201324.","journal-title":"Br J Haematol"},{"key":"1417_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14619-z","volume":"11","author":"SV Radhakrishnan","year":"2020","unstructured":"Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun. 2020;11:798.","journal-title":"Nat Commun"},{"key":"1417_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638288","volume":"11","author":"V Lazaris","year":"2021","unstructured":"Lazaris V, Hatziri A, Symeonidis A, Kypreos KE. The lipoprotein transport system in the pathogenesis of multiple myeloma: advances and challenges. Front Oncol. 2021;11:638288.","journal-title":"Front Oncol"},{"key":"1417_CR9","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.7150\/jca.31357","volume":"10","author":"L Liang","year":"2019","unstructured":"Liang L, Li J, Fu H, Liu X, Liu P. Identification of high serum apolipoprotein A1 as a favorable prognostic indicator in patients with multiple myeloma. J Cancer. 2019;10:4852\u20139.","journal-title":"J Cancer"},{"key":"1417_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00638-w","volume":"8","author":"A Cleynen","year":"2017","unstructured":"Cleynen A, Szalat R, Kemal Samur M, Robiou du Pont S, Buisson L, Boyle E, et al. Expressed fusion gene landscape and its impact in multiple myeloma. Nat Commun. 2017;8:1893.","journal-title":"Nat Commun"},{"key":"1417_CR11","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1182\/blood.V120.21.5013.5013","volume":"120","author":"N Deshet-Unger","year":"2012","unstructured":"Deshet-Unger N, Hiram-Bab S, Ohana YH, Gross M, Souroujon M, Mittelman M, et al. Erythropoietin treatment in multiple myeloma \u2013 friend or foe?. Blood. 2012;120:5013.","journal-title":"Blood"},{"key":"1417_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828041","volume":"12","author":"M Zhang","year":"2022","unstructured":"Zhang M, Qi T, Yang L, Kolarich D, Heisterkamp N. Multi-faceted effects of ST6Gal1 expression on precursor B-lineage acute lymphoblastic leukemia. Front Oncol. 2022;12:828041.","journal-title":"Front Oncol"},{"key":"1417_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14:194.","journal-title":"Blood Cancer J"},{"key":"1417_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67105-3","volume":"10","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Broniowska K, Jessen E, Petterson XM, Bush AG, Gransee J, et al. Metabolomic and lipidomic profiling of bone marrow plasma differentiates patients with monoclonal gammopathy of undetermined significance from multiple myeloma. Sci Rep. 2020;10:10250.","journal-title":"Sci Rep"},{"key":"1417_CR15","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1182\/bloodadvances.2025016120","volume":"9","author":"J Fieggen","year":"2025","unstructured":"Fieggen J, Thakur A, Butler CC, Ramasamy K, Thakurta A, Clifton DA, et al. Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis. Blood Adv. 2025;9:3766\u201370.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01417-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01417-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01417-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:04:30Z","timestamp":1763805870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01417-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01417-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RF reports providing consulting services for AbbVie, Adaptive Biotechnologies, Amgen, Apple, BMS (Celgene), GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron and Sanofi; serving on the scientific advisory board of Caris Life Sciences; serving on the board of directors of Antengene (for profit); and having a patent for fluorescence in situ hybridization in multiple myeloma (\u223c$2000 per year). SK reports providing consulting services (with no personal payments) for AbbVie, Amgen, ArcellX, Beigene, BMS, Carsgen, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanofi, Takeda, and (with personal payments) for CVS Caremark and BD Biosciences; and received clinical trial support to the institution from AbbVie, Amgen, AstraZeneca, BMS, Carsgen, GSK, Gracell Bio, Janssen, Oricell, Roche-Genentech, Sanofi, Takeda, and Telogenomics. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study received approval from the Mayo Clinic Institutional Review Board (IRB# 15-005140) in accordance with federal regulations and the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"202"}}